全球再生醫學·組織再生市場及技術 是由出版商BCC Research在2012年01月所出版的。
這份英文市場調查報告書包含200 Pages 價格從美金4850起跳。
2010年，全球再生醫學·組織再生產品的市場達到559億美元的市場規模。2011年達到598億美元以8.4％的年平均成長率成長，2016年預計將成長為897億美元的市場規模。
本報告提供全球再生醫學·組織再生市場趨勢相關調查分析，現有的再生醫學·組織再生產品種類與概要，地區/國家·再生對象區分·疾病/治療各種類的產品市場分析及預測(∼2016年)，新的產品·設備·治療方法的開發的因素分析，並彙整主要企業簡介等，為您概述為以下內容。
第1章 簡介
第2章 摘要
第3章 簡介:產業
- 概要
- 再生醫學產品概要
- 再生醫學產業詳細內容區分·倒數前幾名市場
第4章 皮膚再生醫學市場
第5章 骨·軟骨·其他結締組織的再生醫學
- 軟骨·其他軟組織·軟骨組織·結締組織(韌帶·肌腱)概要
- 骨骼修復市場概要
第6章 心血管再生醫學的市場
第7章 中樞神經系統(CNS)疾病的再生醫學
第8章 內臟器官再生醫學
第9章 再生醫學產業的新倒數前幾名市場
第10章 美國的再生醫學·組織再生市場
- 皮膚再生醫學產品的市場
- 軟骨·骨再生醫學產品的市場
- 心血管再生醫學產品的市場
- 中樞神經相關的損傷及疾病的再生醫學產品的開發
- 內臟器官再生醫學市場
第11章 歐洲的再生醫學·組織再生市場
- 皮膚再生醫學產品的市場
- 軟骨·骨再生醫學產品的市場
- 心血管再生醫學產品的市場
- 中樞神經相關的損傷及疾病的再生醫學產品的開發
- 內臟器官再生醫學市場
第12章 其他地區的再生醫學·組織再生市場
- 皮膚再生醫學產品的市場
- 軟骨·骨再生醫學產品的市場
- 心血管再生醫學產品的市場
- 中樞神經相關的損傷及疾病的再生醫學產品的開發
- 內臟器官再生醫學市場
第13章 摘要:全球再生醫學·組織再生市場
- 摘要:全球市場
- 摘要:美國市場
- 摘要:歐洲市場
- 摘要:其他地區市場
第14章 主要企業概要
第15章 刊載企業的清單
圖表
Abstract
REPORT HIGHLIGHTS
The global market for tissue engineering and regeneration products reached
$55.9 billion in 2010, is expected to reach $59.8 billion by 2011, and will
further grow to $89.7 billion by 2016 at a compounded annual growth rate
(CAGR) of 8.4%.
The contribution of the U.S region was 45.4% of the total market in 2010 which
was a value of $25.3 billion. The market is expected to reach $26.8 billion by
2011 and will further grow to $40.4 billion by 2016 at a CAGR of 8.5%.
The contribution of the European region was 43.3% of the market in 2010, a
value of $24.2 billion. The market is expected to reach $25.5 billion by 2011
and will further grow to $36.1 billion by 2016 at a CAGR of 7.2%.
REPORT SCOPE
INTRODUCTION
STUDY GOALS AND OBJECTIVES
This report provides an overview of the tissue engineering and regeneration
industry. It describes existing products on the market and offers detailed
analysis of the competitive environments, including new and potential markets
for novel therapies and treatments. The study includes information about
significant industry players, trends, and obstacles, and discusses factors
affecting the development of new products, devices, and therapies.
REASONS FOR DOING THIS STUDY
Tissue engineering is a multidisciplinary study involving biology, medicine,
and engineering to create products and devices that will improve or replace
biological functions and organs. The first experiments in tissue engineering
date back to the 1960s. More than a decade ago, the industry introduced the
first FDA-approved, tissue-engineered commercial product - artificial skin
substitute.
Although tissue engineering has enormous commercial potential, it seems that
this market develops at a very slow pace. After the introduction of skin
substitutes and cartilage regeneration products in the last decade or so, not
much progress has been made in the industry. Moreover, some of the products
have been discontinued. One of the main reasons for this slow development is
the biological complexity of growing organs and tissue replacements. In
addition, current technologies are not efficient enough to make these products
cost-effective alternatives.
Overall, the tissue engineering market is a heterogeneous industry and can be
divided into number of subsectors. Skin substitutes are a relatively
developed segment, while tissue-engineered products for the nervous system
comprise a sector that is still in a preliminary stage. Recent developments
in regeneration research, especially stem cell research, give hope that new
scientific breakthroughs will lead to innovative products.
In summary, this report will highlight the main segments of the tissue
engineering and regeneration industry, its major market participants, and
current and future market trends. The report will also highlight specific
geographical regions that have individual market characteristics. Drivers and
challenges in each sector of this industry will be discussed in detail,
including forecasts for the next 5 years.
SCOPE AND FORMAT
This report is a current and important business tool for evaluating new,
commercial opportunities in the tissue engineering market. The geographic
scope of this study covers the U.S., Europe, and other parts of the world.
The market is complex and consists of many sectors, each affected differently
by scientific and technological developments. The report identifies the
primary positive and negative factors in each sector and forecasts future
trends, products, and therapies for each category.
METHODOLOGY AND INFORMATION SOURCES
The research methodology was more qualitative than quantitative in nature, and
employed a triangulating approach, which strengthens validity. Initially, a
comprehensive and exhaustive search of the literature on drug discovery and
already marketed products was conducted. These secondary sources included
drug discovery and science-related journals, textbooks, press releases,
marketing literature, other product/promotional literature, annual reports,
security analyst reports, and other publications. A patent search and
analysis was also conducted.
In a second phase, a series of semi-structured interviews was conducted with
company representatives, bench scientists, marketing representatives, and
other personnel at biotech and pharmaceutical companies. Other resources
included academic institutions and technology and consulting companies, which
were a rich source of data. Subsequent analysis of the documents and
interview notes was iterative.
INTENDED AUDIENCE
This report is intended for business development professionals, entrepreneurs,
and other investment groups in order to fully understand and evaluate properly
each segment in the tissue engineering and regeneration industry. It provides
companies with new insights into competitors' positions and discusses new
opportunities otherwise overlooked or less known to the public.
ANALYST CREDENTIALS
Dr. Marianna Tcherpakov has more than 7 years of experience as a bench
scientist specializing in the area of biochemistry, cell biology, and
industrial assay development. She has contributed to a number of scientific
publications and holds several patents. She has expertise as an assay
development scientist and is familiar with different research field trends and
probable future developments.
Table of Contents
Chapter- 1: INTRODUCTION - Complimentary
- STUDY GOALS AND OBJECTIVES
- REASONS FOR DOING THIS STUDY
- SCOPE AND FORMAT
- METHODOLOGY AND INFORMATION SOURCES
- INTENDED AUDIENCE
- ANALYST CREDENTIALS
- RELATED BCC REPORTS
- BCC ON-LINE SERVICES
- DISCLAIMER
Chapter- 2: SUMMARY
- Table 0 : GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
THROUGH 2016
- Figure 0 : GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
2009-2016
Chapter- 3: INTRODUCTION TO TISSUE ENGINEERING AND REGENERATION INDUSTRY
- OVERVIEW
- OVERVIEW OF TISSUE ENGINEERING PRODUCTS
- SECTORS AND SUBMARKETS IN THE TISSUE ENGINEERING INDUSTRY
Chapter- 4: SKIN TISSUE ENGINEERING MARKET9$327
- OVERVIEW
- Table 5 : STATISTICS FOR SKIN DAMAGE MEDICAL CONDITIONS IN THE U.S. AND
WORLDWIDE, 2011
Chapter- 5: TISSUE ENGINEERING FOR BONE, CARTILAGE, AND OTHER CONNECTIVE TISSUES
- OVERVIEW OF CARTILAGE AND OTHER SOFT, MUSCULOSKELETAL CONNECTIVE TISSUES
(LIGAMENTS, TENDONS)
- OVERVIEW OF BONE REPAIR MARKET
- Table 16 : STATISTICS FOR BONE DAMAGE AND RELATED DISEASES, 2011
- Table 17 : GLOBAL MARKET FOR ORTHOBIOLOGICS AND TISSUE-ENGINEERED
PRODUCTS, THROUGH 2016
Chapter- 6: TISSUE ENGINEERING MARKET FOR CVD
Chapter- 7: TISSUE ENGINEERING FOR CENTRAL NERVOUS SYSTEM (CNS) DISEASES
Chapter- 8: TISSUE ENGINEERING FOR INTERNAL ORGANS
- OVERVIEW
- Table 33 : GLOBAL MARKET FOR ORGAN AND TISSUE TRANSPLANTATION PRODUCTS,
THROUGH 2016
- Table 34 : STATISTICS FOR DONORS AND TRANSPLANTATION IN THE U.S., 2008 -
2011
- Table 35 : AVERAGE FIRST-YEAR COSTS OF TRANSPLANT PROCEDURES IN THE U.S.
Chapter- 9: EMERGING SUBMARKETS IN TISSUE ENGINEERING INDUSTRY
- OVERVIEW
- Table 42 : GLOBAL MARKET FOR ANTI-AGING PRODUCTS AND SERVICES, THROUGH 2016
- Table 43 : GEOGRAPHICAL DISTRIBUTION OF ANTI-AGING MARKET
Chapter- 10: U.S. MARKET FOR TISSUE ENGINEERING AND REGENERATION
- U.S. MARKET FOR SKIN TISSUE ENGINEERING PRODUCTS
- U.S. MARKET FOR CARTILAGE AND BONE TISSUE ENGINEERING PRODUCTS
- U.S. MARKET FOR TISSUE ENGINEERING PRODUCTS FOR CVD
- U.S. MARKET FOR DEVELOPMENT OF TISSUE ENGINEERING PRODUCTS FOR CNS-RELATED
INJURIES AND DISEASES
- U.S. MARKET FOR TISSUE ENGINEERING FOR INTERNAL ORGANS
- Table 58 : STATISTICS FOR ORGAN DONATIONS AND TRANSPLANTATIONS IN THE
U.S., 2008 - 2011
- Table 59 : U.S. MARKET FOR TISSUE ENGINEERING IN ORGAN TRANSPLANTATION,
THROUGH 2016
- Table 60 : NUMBER OF DIFFERENT ORGAN TRANSPLANTATIONS IN U.S., 2009
- Table 61 : STATISTICS ON MEDICAL CONDITIONS REQUIRING ORGAN
TRANSPLANTATION IN THE U.S., 2010
- Table 62 : COMPANIES SELLING OR DEVELOPING PRODUCT FOR TISSUE ENGINEERING
FOR INTERNAL ORGAN REPLACEMENT
Chapter- 11: EUROPEAN MARKET FOR TISSUE ENGINEERING AND REGENERATION
- EUROPEAN MARKET FOR SKIN TISSUE ENGINEERING PRODUCTS
- EUROPEAN MARKET FOR CARTILAGE AND BONE TISSUE ENGINEERING PRODUCTS
- EUROPEAN MARKET FOR TISSUE ENGINEERING PRODUCTS FOR CVD
- EUROPEAN MARKET FOR TISSUE-ENGINEERING PRODUCTS FOR CNS-RELATED INJURIES
AND DISORDERS
- EUROPEAN MARKET FOR TISSUE ENGINEERING FOR INTERNAL ORGANS
- Table 79 : ORGAN DONATIONS STATISTICS FOR DIFFERENT EUROPEAN COUNTRIES,
2009
- Table 80 : ORGAN TRANSPLANTATION STATISTICS IN DIFFERENT EUROPEAN
COUNTRIES, 2009
- Table 81 : EUROPEAN MARKET FOR TISSUE ENGINEERING IN ORGAN
TRANSPLANTATION, THROUGH 2016
- Table 82 : PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN
COUNTRIES, 2010
- Table 83 : EUROPEAN COMPANIES SELLING OR DEVELOPING PRODUCT FOR TISSUE
ENGINEERING FOR INTERNAL ORGAN REPLACEMENT
Chapter- 12: REST OF WORLD (ROW) MARKET FOR TISSUE ENGINEERING AND REGENERATION
- REST OF WORLD (ROW) MARKET FOR SKIN TISSUE ENGINEERING PRODUCTS
- ROW MARKET FOR CARTILAGE AND BONE TISSUE ENGINEERING PRODUCTS
- ROW MARKET FOR TISSUE ENGINEERING PRODUCTS FOR CVD
- ROW MARKET FOR TISSUE ENGINEERING PRODUCTS FOR CNS-RELATED INJURIES AND
DISEASES
- ROW MARKET FOR TISSUE ENGINEERING FOR INTERNAL ORGANS
- Table 96 : ORGAN DONATIONS STATISTICS FOR DIFFERENT COUNTRIES IN ROW, 2009
- Table 97 : ORGAN TRANSPLANTATION STATISTICS FOR DIFFERENT COUNTRIES IN
ROW, 2009
- Table 98 : ROW MARKET FOR TISSUE ENGINEERING BASED ON ORGAN
TRANSPLANTATIONS, THROUGH 2016
- Table 99 : PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT COUNTRIES, 2010
- Table 100 : COMPANIES DEVELOPING TISSUE ENGINEERING PRODUCTS FOR INTERNAL
ORGAN REPLACEMENT
Chapter- 13: SUMMARY OF GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION
- SUMMARY OF GLOBAL MARKET
- SUMMARY OF U.S. MARKET IN TISSUE ENGINEERING AND REGENERATION
- SUMMARY OF EUROPEAN MARKET IN TISSUE ENGINEERING AND REGENERATION
- SUMMARY OF ROW MARKET IN TISSUE ENGINEERING AND REGENERATION
- Table 106 : ROW MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
THROUGH 2016
- Figure 4 : ROW MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
2009 - 2016
Chapter- 14: OVERVIEW OF SELECTED COMPANIES
- ADVANCED BIOHEALING (A SHIRE PHARMACEUTICAL COMPANY)
- CO.DON AG
- GENZYME CORP. (A SANOFI-AVENTIS COMPANY)
- MEDTRONIC
- RENEURON GROUP
- STRYKER CORP.
Chapter- 15: LIST OF THE COMPANIES MENTIONED IN REPORT
- 3DM
- AAP IMPLANTANTE AG
- AASTROM BIOSCIENCES, INC.
- ACORDA THERAPEUTICS, INC.
- ADVANCED CELL TECHNOLOGY, INC.
- ADVANCED MEDICAL SOLUTIONS GROUP, PLC
- ALDAGEN, INC.
- ALLERGAN, INC.
- APERION BIOLOGICS
- ARTHRO-KINETICS
- ARTERIOCYTE
- AVITA MEDICAL
- BAXTER HEALTHCARE CORP.
- BEFUTUR BIOTECHNOLOGIES
- BETA-CELL NV
- BETA-O2 TECHNOLOGIES LTD
- BIO NOVA INTERNATIONAL PTY., LTD.
- BIOCOMPOSITES, LTD.
- BIOCORAL, INC.
- BIOFISICA, INC.
- BIOHEART, INC.
- BIOMET, INC.
- BIOTIME, INC.
- BIOTISSUE TECHNOLOGIES GMBH
- BONALIVE BIOMATERIALS, LTD.
- BOSTON SCIENTIFIC CORP.
- B. BRAUN MEDICAL, INC.
- BREONICS, INC.
- CAPRICOR, INC.
- CARDIUM THERAPEUTICS, INC.
- CELLERIX SA
- CELLSEED, INC.
- CELLULAR DYNAMICS INTERNATIONAL
- CERAPEDICS, INC.
- CERCO MEDICAL, LLC
- COOK GROUP, INC.
- C.R. BARD, INC.
- CRYOLIFE, INC.
- CYTOGRAFT TISSUE ENGINEERING, INC.
- CYTONET GMBH & CO. KG
- CYTORI THERAPEUTICS, INC.
- CURASAN AG
- DEGRADABLE SOLUTIONS AG
- DEVELOGEN AG
- EXACTECH, INC.
- EXCORP MEDICAL
- FIBROGEN, INC.
- FIDIA ADVANCED BIOPOLYMERS/FIDIA FARMACEUTICI SPA
- FORTICELL BIOSCIENCE, INC.
- GAMIDA CELL, LTD.
- GERON CORP.
- GLYCOTEX, INC.
- HEPALIFE TECHNOLOGIES/AQUAMED TECHNOLOGIES, INC./ALLIQUA, INC.
- HISTOCELL TISSUE ENGINEERING
- HUMACYTE, INC.
- HYBRID ORGAN GMBH
- INCYTU, INC.
- INION OY
- INNOVACELL BIOTECHNOLOGIE AG
- INTEGRA LIFE SCIENCES
- INTERCYTEX
- KENSEY NASH CORP.
- KERECIS
- KINETIC CONCEPTS, INC.
- KUROS BIOSURGERY AG
- LABORATORIES GENEVRIER
- LIFECELL CORP.
- MAXCYTE INC
- MESOBLAST LTD.
- NELLONE THERAPEUTICS, INC.
- NEURALSTEM
- NEUROGENERATION
- ORGANOGENESIS, INC.
- ORGANOVO, INC.
- OSIRIS THERAPEUTICS, INC.
- PIONEER SURGICAL TECHNOLOGY
- PLURISTEM THERAPEUTICS, INC.
- POLYGANICS
- PRONEURON BIOTECHNOLOGIES, INC.
- Q-MED
- REINNERVATE
- RENOVO
- REVIVICOR, INC.
- RTI BIOLOGICS
- SERNOVA CORP.
- SKINETHIC LABORATORIES
- SMITH & NEPHEW
- STRAUMANN HOLDINGS/INSTITUT STRAUMANN AG
- SYNOVIS LIFE TECHNOLOGIES, INC.
- TEI BIOSCIENCES, INC.
- TENGION, INC.
- TEPHA, INC.
- TETEC TISSUE ENGINEERING TECHNOLOGIES AG
- TIGENIX NV
- TISSUEMED
- VIACYTE
- VITAL THERAPIES, INC.
- VITROLIFE
- ZIMMER, INC.
List of Tables
- Summary Table : GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION
PRODUCTS, THROUGH 2016
- Table 1 : GLOBAL MARKET RELATED TO STEM CELL RESEARCH, THROUGH 2016
- Table 2 : GLOBAL MARKET FOR BIOMATERIALS, THROUGH 2016
- Table 3 : DIFFERENCES IN REGULATORY APPROVAL: U.S. VS. EUROPE
- Table 4 : HEALTHCARE SYSTEMS OF DIFFERENT EUROPEAN AND REST OF WORLD
COUNTRIES
- Table 5 : STATISTICS FOR SKIN DAMAGE MEDICAL CONDITIONS IN THE U.S. AND
WORLDWIDE, 2011
- Table 6 : EXAMPLES OF ACELLULAR SKIN TISSUE-ENGINEERED PRODUCTS ON THE
MARKET
- Table 7 : EXAMPLES OF CELLULAR SKIN TISSUE-ENGINEERED PRODUCTS ON THE
MARKET
- Table 8 : SALES OF DERMAGRAFT, THROUGH 2016
- Table 9 : DISTRIBUTION OF WOUND CARE MARKET ACCORDING TO DIFFERENT
CATEGORIES
- Table 10 : MARKET FOR SKIN TISSUE-ENGINEERED PRODUCTS WORLDWIDE, THROUGH
2016
- Table 11 : GEOGRAPHICAL DISTRIBUTION OF SKIN TISSUE ENGINEERING MARKET
- Table 12 : STATISTICS FOR CARTILAGE DAMAGE WORLDWIDE
- Table 13 : GLOBAL MARKET FOR CARTILAGE REPAIR, THROUGH 2016
- Table 14 : GEOGRAPHICAL DISTRIBUTION OF CARTILAGE REPLACEMENT MARKET
- Table 15 : SALES OF CARTICEL BY GENZYME CORP., 2005 - 2008
- Table 16 : STATISTICS FOR BONE DAMAGE AND RELATED DISEASES, 2011
- Table 17 : GLOBAL MARKET FOR ORTHOBIOLOGICS AND TISSUE-ENGINEERED
PRODUCTS, THROUGH 2016
- Table 18 : SALES OF SELECTED TISSUE-ENGINEERED PRODUCTS FOR BONE REPAIR
- Table 19 : GEOGRAPHICAL DISTRIBUTION OF TISSUE-ENGINEERED BONE REPAIR
MARKET
- Table 20 : GLOBAL MARKET FOR TISSUE ENGINEERING PRODUCTS FOR BONE,
CARTILAGE AND OTHER CONNECTIVE TISSUES, THROUGH 2016
- Table 21 : GLOBAL HEART VALVE MARKET, THROUGH 2016
- Table 22 : GEOGRAPHICAL DISTRIBUTION FOR HEART VALVE MARKET
- Table 23 : GLOBAL MARKET FOR VASCULAR SYNTHETIC GRAFTS, THROUGH 2016
- Table 24 : EXAMPLES OF COMPANIES DEVELOPING CELL THERAPIES FOR CVD
- Table 25 : GLOBAL MARKET FOR TISSUE-ENGINEERED PRODUCTS FOR CVD, THROUGH
2016
- Table 26 : STATISTICS FOR SCI WORLDWIDE, 2011
- Table 27 : SALES OF NEURAL GRAFT PRODUCTS FROM INTEGRA LIFE SCIENCES,
THROUGH 2016
- Table 28 : STATISTICS FOR NEURODEGENERATIVE DISEASES WORLDWIDE, 2011
- Table 29 : GLOBAL MARKET FOR THERAPEUTICS FOR NEURODEGENERATIVE DISORDERS,
THROUGH 2015
- Table 30 : CURRENT GLOBAL MARKET FOR TISSUE-ENGINEERED PRODUCTS FOR
CNS-RELATED INJURIES AND DISEASES, THROUGH 2016
- Table 31 : GEOGRAPHICAL DISTRIBUTION OF MARKET FOR TISSUE ENGINEERING
PRODUCTS FOR CNS
- Table 32 : SELECTED STEM CELL THERAPIES ENTERING CLINICAL TRIALS
- Table 33 : GLOBAL MARKET FOR ORGAN AND TISSUE TRANSPLANTATION PRODUCTS,
THROUGH 2016
- Table 34 : STATISTICS FOR DONORS AND TRANSPLANTATION IN THE U.S., 2008 -
2011
- Table 35 : AVERAGE FIRST-YEAR COSTS OF TRANSPLANT PROCEDURES IN THE U.S.
- Table 36 : MARKET FOR TISSUE ENGINEERING IN ORGAN TRANSPLANTATION FOR,
THROUGH 2016
- Table 37 : U.S. STATISTICS FOR KIDNEY DISEASES, 2010
- Table 38 : STATISTICS ASSOCIATED WITH LIVER FAILURE IN U.S., 2011
- Table 39 : EXAMPLES OF ARTIFICIAL LIVER SUPPORT SYSTEMS
- Table 40 : STATISTICS FOR PANCREATIC CANCER AND DIABETES IN THE U.S., 2010
- Table 41 : GLOBAL MARKET FOR DIABETES MELLITUS, THROUGH 2016
- Table 42 : GLOBAL MARKET FOR ANTI-AGING PRODUCTS AND SERVICES, THROUGH 2016
- Table 43 : GEOGRAPHICAL DISTRIBUTION OF ANTI-AGING MARKET
- Table 44 : GLOBAL MARKET FOR DENTAL IMPLANTS, THROUGH 2016
- Table 45 : GLOBAL MARKET FOR COSMETIC PROCEDURES AND PRODUCTS, THROUGH 2016
- Table 46 : CURRENT U.S. STATISTICS FOR SKIN DAMAGE CONDITIONS REQUIRING
WOUND CARE, 2011
- Table 47 : MARKET FOR SKIN TISSUE-ENGINEERED PRODUCTS IN U.S., THROUGH 2016
- Table 48 : EXAMPLES OF U.S. COMPANIES SELLING OR DEVELOPING SKIN
TISSUE-ENGINEERED PRODUCTS
- Table 49 : STATISTICS FOR BONE DAMAGE AND RELATED DISEASES IN THE U.S. 2011
- Table 50 : U.S. MARKET FOR TISSUE-ENGINEERED PRODUCTS FOR CARTILAGE AND
BONE REPAIR, THROUGH 2016
- Table 51 : EXAMPLES OF U.S. COMPANIES MARKETING OR DEVELOPING
TISSUE-ENGINEERED PRODUCTS FOR CARTILAGE AND BONE REPAIR
- Table 52 : STATISTICS FOR CVD IN U.S., 2010 AND 2011
- Table 53 : U.S. MARKET VALUE FOR TISSUE-ENGINEERED PRODUCTS FOR CVD,
THROUGH 2016
- Table 54 : EXAMPLES OF U.S. COMPANIES IN TISSUE ENGINEERING MARKET FOR CVD
- Table 55 : U.S. STATISTICS FOR DIFFERENT CNS MEDICAL CONDITIONS
- Table 56 : U.S. MARKET FOR TISSUE-ENGINEERED PRODUCTS FOR CNS, THROUGH 2016
- Table 57 : EXAMPLES OF COMPANIES IN U.S. DEVELOPING TISSUE-ENGINEERED
PRODUCTS FOR CNS DISEASES
- Table 58 : STATISTICS FOR ORGAN DONATIONS AND TRANSPLANTATIONS IN THE
U.S., 2008 - 2011
- Table 59 : U.S. MARKET FOR TISSUE ENGINEERING IN ORGAN TRANSPLANTATION,
THROUGH 2016
- Table 60 : NUMBER OF DIFFERENT ORGAN TRANSPLANTATIONS IN U.S., 2009
- Table 61 : STATISTICS ON MEDICAL CONDITIONS REQUIRING ORGAN
TRANSPLANTATION IN THE U.S., 2010
- Table 62 : COMPANIES SELLING OR DEVELOPING PRODUCT FOR TISSUE ENGINEERING
FOR INTERNAL ORGAN REPLACEMENT
- Table 63 : CURRENT STATISTICS FOR SKIN DAMAGE CONDITIONS REQUIRING WOUND
CARE IN EUROPE, 2011
- Table 64 : EUROPEAN MARKET FOR SKIN TISSUE-ENGINEERED PRODUCTS, THROUGH
2016
- Table 65 : EXAMPLES OF EUROPEAN COMPANIES SELLING OR DEVELOPING SKIN
TISSUE-ENGINEERED PRODUCTS
- Table 66 : STATISTICS FOR BONE DAMAGE AND RELATED DISEASES IN DIFFERENT
EUROPEAN COUNTRIES
- Table 67 : EUROPEAN MARKET FOR TISSUE ENGINEERING PRODUCTS FOR BONE AND
CARTILAGE REPAIR, THROUGH 2016
- Table 68 : DISTRIBUTION OF MARKET FOR BONE AND CARTILAGE TISSUE-ENGINEERED
PRODUCTS AMONG DIFFERENT COUNTRIES
- Table 69 : EXAMPLES OF EUROPEAN COMPANIES MARKETING OR DEVELOPING
TISSUE-ENGINEERED PRODUCTS FOR CARTILAGE AND BONE REPAIR
- Table 70 : STATISTICS FOR CVD IN EUROPE, 2011
- Table 71 : RATE OF DEATH FROM HEART DISEASE IN DIFFERENT EUROPEAN
COUNTRIES, 2011
- Table 72 : MARKET VALUE FOR TISSUE-ENGINEERED PRODUCTS FOR CVD IN EUROPE,
THROUGH 2016
- Table 73 : EXAMPLES OF COMPANIES MARKETING OR DEVELOPING TISSUE-ENGINEERED
PRODUCTS FOR CVD IN EUROPE
- Table 74 : STATISTICS FOR CNS DISORDERS AND INJURIES IN EUROPE, 2011
- Table 75 : STATISTICS FOR SCI AND PARKINSON'S DISEASE IN DIFFERENT
EUROPEAN COUNTRIES, 2011
- Table 76 : CURRENT EUROPEAN MARKET FOR TISSUE-ENGINEERED PRODUCTS FOR
CNS-RELATED INJURIES AND DISORDERS, THROUGH 2016
- Table 77 : EXAMPLES OF STEM CELL POLICIES IN DIFFERENT EUROPEAN COUNTRIES
- Table 78 : EXAMPLES OF COMPANIES IN EUROPE DEVELOPING PRODUCTS IN TISSUE
ENGINEERING AND REGENERATION FOR CNS DISORDERS AND INJURIES
- Table 79 : ORGAN DONATIONS STATISTICS FOR DIFFERENT EUROPEAN COUNTRIES,
2009
- Table 80 : ORGAN TRANSPLANTATION STATISTICS IN DIFFERENT EUROPEAN
COUNTRIES, 2009
- Table 81 : EUROPEAN MARKET FOR TISSUE ENGINEERING IN ORGAN
TRANSPLANTATION, THROUGH 2016
- Table 82 : PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT EUROPEAN
COUNTRIES, 2010
- Table 83 : EUROPEAN COMPANIES SELLING OR DEVELOPING PRODUCT FOR TISSUE
ENGINEERING FOR INTERNAL ORGAN REPLACEMENT
- Table 84 : GLOBAL STATISTICS FOR SKIN-RELATED MEDICAL CONDITIONS, 2011
- Table 85 : ROW MARKET FOR SKIN TISSUE-ENGINEERED PRODUCTS, THROUGH 2016
- Table 86 : STATISTICS FOR BONE DAMAGE AND RELATED DISEASES IN DIFFERENT
PARTS OF THE WORLD
- Table 87 : ROW MARKET FOR TISSUE ENGINEERING PRODUCTS FOR BONE AND
CARTILAGE REPAIR, THROUGH 2016
- Table 88 : EXAMPLES OF COMPANIES MARKETING OR DEVELOPING TISSUE-ENGINEERED
PRODUCTS FOR CARTILAGE AND BONE REPAIR IN DIFFERENT REGIONS OF THE WORLD
- Table 89 : STATISTICS FOR CVD IN DIFFERENT REGIONS OF THE WORLD, 2011
- Table 90 : ROW MARKET VALUE FOR TISSUE-ENGINEERED PRODUCTS FOR CVD,
THROUGH 2016
- Table 91 : EXAMPLES OF COMPANIES THAT MANUFACTURE/DEVELOP
TISSUE-ENGINEERED PRODUCTS FOR CVD IN DIFFERENT COUNTRIES IN ROW
- Table 92 : STATISTICS FOR CNS DISORDERS AND INJURIES WORLDWIDE, 2011
- Table 93 : CURRENT ROW MARKET FOR TISSUE-ENGINEERED PRODUCTS FOR CNS
RELATED INJURIES AND DISEASES, THROUGH 2016
- Table 94 : EXAMPLES OF STEM CELL POLICIES IN DIFFERENT COUNTIES IN ROW
- Table 95 : EXAMPLES OF ROW COMPANIES DEVELOPING PRODUCTS IN TISSUE
ENGINEERING/REGENERATION FOR CNS DISORDERS AND INJURIES
- Table 96 : ORGAN DONATIONS STATISTICS FOR DIFFERENT COUNTRIES IN ROW, 2009
- Table 97 : ORGAN TRANSPLANTATION STATISTICS FOR DIFFERENT COUNTRIES IN
ROW, 2009
- Table 98 : ROW MARKET FOR TISSUE ENGINEERING BASED ON ORGAN
TRANSPLANTATIONS, THROUGH 2016
- Table 99 : PREVALENCE OF DIABETIC PATIENTS IN DIFFERENT COUNTRIES, 2010
- Table 100 : COMPANIES DEVELOPING TISSUE ENGINEERING PRODUCTS FOR INTERNAL
ORGAN REPLACEMENT
- Table 101 : GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION
PRODUCTS, THROUGH 2016
- Table 102 : EXAMPLES OF MAIN MARKET PARTICIPANTS IN THE TISSUE ENGINEERING
INDUSTRY
- Table 103 : U.S. MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
THROUGH 2016
- Table 104 : EUROPEAN MARKET FOR TISSUE ENGINEERING AND REGENERATION
PRODUCTS, THROUGH 2016
- Table 105 : PERCENTAGE OF VENTURES IN TISSUE ENGINEERING PRODUCT
DEVELOPMENT IN DIFFERENT EUROPEAN COUNTRIES
- Table 106 : ROW MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
THROUGH 2016
List of Figures
- Summary Figure : GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION
PRODUCTS, 2009-2016
- Figure 1 : GLOBAL MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
2009 - 2016
- Figure 2 : U.S. MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
2009 - 2016
- Figure 3 : EUROPEAN MARKET FOR TISSUE ENGINEERING AND REGENERATION
PRODUCTS, 2009 - 2016
- Figure 4 : ROW MARKET FOR TISSUE ENGINEERING AND REGENERATION PRODUCTS,
2009 - 2016
全球的再生醫學市場於2016年將達到897億美元
2012年02月10日
Global Information Inc.開始代理銷售由BCC Research，所發行的調查報告「Tissue Engineering and Regeneration: Technologies and Global Markets (全球再生醫學·組織再生市場及技術)」。
全球的再生醫學•組織再生市場在2011年約為600億美元的規模。之後預料將以年複合成長率（CAGR）8.4%成長，在2016年達到897億美元。
再生醫學市場分為美國、歐洲、以及其他等3個地區。
美國地區在2011年為268億美元的規模，而之後預測將以CAGR 8.5%成長，在2016年達到將近404億美元。
歐洲地區在2011年約為255億美元的規模，而之後預測將以CAGR 7.2%成長，在2016年達到將近361億美元的規模。
全球其他地區在2011年為75億美元的規模，而之後預測將以CAGR 11.9%成長，在2016年達到約132億美元。
再生醫學包含生物學、醫學、以及工學的領域，為創造進行活體機能提昇和置換的產品與裝置的醫療領域。
再生醫療產品透過工學手法以組合細胞和素材等所開發。
再生醫學一詞代表廣泛的應用，但是實際上，與修復•置換一部份或全部的骨頭、軟骨、血管、囊胞和皮膚等組織的應用有密切相關。
|
